Cadence Capital Management’s Standard BioTools LAB Stock Holding History

Cadence Capital Management’s Portfolio LAB Stock Details LAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-231,316	Closed	-$805K	–	448
2019 Q4	$805K	Sell	231,316 -36,848	-14%	-$130K	0.09%	302
2019 Q3	$1.24M	Buy	268,164 +2,928	+1%	+$23.1K	0.18%	219
2019 Q2	$3.27M	Buy	265,236 +122,674	+86%	+$1.56M	0.33%	66
2019 Q1	$1.9M	Buy	+142,562	New	+$1.5M	0.17%	181
2015 Q2	–	Sell	-69,340	Closed	-$2.92M	–	637
2015 Q1	$2.92M	Buy	+69,340	New	+$2.74M	0.18%	155

Other funds holding LAB

Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ICM

Indaba Capital Management San Francisco, California $33.8M AUM 33.83% 1-Year Est. Return

EIP

Easterly Investment Partners Beverly, Massachusetts $1.31B AUM 18.17% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Cadence Capital Management's LAB Position: Q1 2020 in Review

Cadence Capital Management sold out of Standard BioTools (LAB) in Q1 2020, closing a stake of 231,316 shares — an estimated $805K sold.

Cadence Capital Management first reported a position in LAB in Q1 2015 and held it in 5 quarters. The position peaked at $3.27M in Q2 2019. 103 funds tracked by Wall St. Rank hold LAB as of Q1 2020.

Cadence Capital Management reported no remaining Standard BioTools position as of Q1 2020 after selling out during the quarter.
Cadence Capital Management sold 231,316 Standard BioTools shares in Q1 2020, an estimated $805K.
Cadence Capital Management first reported a position in Standard BioTools in Q1 2015 and held it in 5 quarters.
Cadence Capital Management's Standard BioTools position peaked at $3.27M in Q2 2019.
103 funds tracked by Wall St. Rank held Standard BioTools as of Q1 2020.

Based on Cadence Capital Management's 13F filing for Q1 2020, filed 4 May 2020.